{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T11:36:25Z","timestamp":1780572985006,"version":"3.54.1"},"reference-count":65,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2017,10,1]],"date-time":"2017-10-01T00:00:00Z","timestamp":1506816000000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["CM15\/00195"],"award-info":[{"award-number":["CM15\/00195"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.cmi.2016.09.017","type":"journal-article","created":{"date-parts":[[2016,9,25]],"date-time":"2016-09-25T00:08:10Z","timestamp":1474762090000},"page":"839-845","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":40,"title":["Role of assessing liver fibrosis in management of chronic hepatitis C virus infection"],"prefix":"10.1016","volume":"22","author":[{"given":"I.","family":"Carmona","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Cordero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ampuero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Romero-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2016.09.017_bib1","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.jhep.2015.03.025","article-title":"EASL recommendations on treatment of hepatitis C 2015","volume":"63","author":"European Association for Study of Liver","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib2","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1093\/infdis\/jis385","article-title":"Chronic hepatitis C virus infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study","volume":"206","author":"Lee","year":"2012","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.cmi.2016.09.017_bib3","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/hep.27950","article-title":"Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus","volume":"62","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib4","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0140-6736(96)07642-8","article-title":"Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups","volume":"349","author":"Poynard","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2016.09.017_bib5","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/hep.22375","article-title":"Estimation of stage-specific fibrosis progression rates in chronic hepatitis C virus infection: a meta-analysis and meta-regression","volume":"48","author":"Thein","year":"2008","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib6","doi-asserted-by":"crossref","first-page":"1699714","DOI":"10.1053\/j.gastro.2008.02.069","article-title":"Disease progression in chronic hepatitis C: modifiable and nonmodifiable factors","volume":"134","author":"Missiha","year":"2008","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.09.017_bib7","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1136\/gut.2003.021691","article-title":"Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study","volume":"53","author":"Ryder","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.cmi.2016.09.017_bib8","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/gast.2003.50018","article-title":"Progression of fibrosis in chronic hepatitis C","volume":"124","author":"Ghany","year":"2003","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.09.017_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/j.1365-2893.2005.00598.x","article-title":"Predicting progressive hepatic fibrosis stage on subsequent liver biopsy in chronic hepatitis C virus infection","volume":"12","author":"Collier","year":"2005","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cmi.2016.09.017_bib10","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.hep.2003.09.022","article-title":"Sampling variability of liver fibrosis in chronic hepatitis C","volume":"38","author":"Bedossa","year":"2003","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib11","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.jhep.2015.04.006","article-title":"Non-invasive tests for evaluation of liver disease severity and prognosis","volume":"63","author":"EASL-ALEH Clinical Practice Guidelines","year":"2015","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib12","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1053\/j.gastro.2004.11.018","article-title":"Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C","volume":"128","author":"Castera","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.09.017_bib13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2009.11.008","article-title":"Prospective comparison of two algorithms combining non-invasive methods for staging liver fibrosis in chronic hepatitis C","volume":"52","author":"Castera","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib14","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1002\/hep.24654","article-title":"Comparison of eight diagnostic algorithms for liver fibrosis in hepatitis C: new algorithms are more precise and entirely noninvasive","volume":"55","author":"Boursier","year":"2012","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib15","first-page":"975","article-title":"Liver stiffness measurements to assess progression of fibrosis in HCV-infected patients with inherited bleeding disorders","volume":"17","author":"Fransen van de Putte","year":"2011","journal-title":"Haemophilia"},{"key":"10.1016\/j.cmi.2016.09.017_bib16","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2893.2011.01531.x","article-title":"Fibrosis progression under maintenance interferon in hepatitis C is better detected by blood test than liver morphometry","volume":"19","author":"Cal\u00e8s","year":"2012","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cmi.2016.09.017_bib17","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1002\/hep.27069","article-title":"Evolution of noninvasive tests of liver fibrosis is associated with prognosis in patients with chronic hepatitis C","volume":"60","author":"Vergniol","year":"2014","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib18","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.jhep.2010.04.024","article-title":"Low virological response and high relapse rates in hepatitis C genotype 1 patients with advanced fibrosis despite adequate therapeutic dosing","volume":"53","author":"Cheng","year":"2010","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib19","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1053\/j.gastro.2014.03.051","article-title":"Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis","volume":"147","author":"H\u00e9zode","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.09.017_bib20","doi-asserted-by":"crossref","first-page":"6513","DOI":"10.1128\/JVI.02276-06","article-title":"Progression of fibrosis during chronic hepatitis C is associated with rapid virus evolution","volume":"81","author":"Wang","year":"2007","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.cmi.2016.09.017_bib21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.4254\/wjh.v7.i3.377","article-title":"Angiogenesis and liver fibrosis","volume":"7","author":"Elpek","year":"2015","journal-title":"World J Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib22","doi-asserted-by":"crossref","first-page":"2164","DOI":"10.1038\/ajg.2010.294","article-title":"Peginterferon plus ribavirin and sustained virological response in HCV-related cirrhosis: outcomes and factors predicting response","volume":"105","author":"Fern\u00e1ndez-Rodr\u00edguez","year":"2010","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.cmi.2016.09.017_bib23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.clpt.2006.05.006","article-title":"Liver disease selectively modulates cytochrome P450\u2013mediated metabolism","volume":"80","author":"Frye","year":"2006","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.09.017_bib24","unstructured":"Babusis D, Curry M, Denning J, Park Y, Murakami E, Afchal NH, et\u00a0al. Nucleotide Analog Levels in Liver Explants From HCV Infected Subjects Undergoing Liver Transplantation After Up to 24 Weeks Sofosbuvir (GS-7977) With Ribavirin Treatment. Abstract presented at the 64rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Washington, DC, USA, Nov 1\u20135 2013."},{"key":"10.1016\/j.cmi.2016.09.017_bib25","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.jhep.2014.08.010","article-title":"Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance","volume":"61","author":"Albillos","year":"2014","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib26","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/jvh.12510","article-title":"Achieving sustained virologic response after interferon-free hepatitis C virus treatment correlates with hepatic interferon gene expression changes independent of cirrhosis","volume":"23","author":"Meissner","year":"2016","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cmi.2016.09.017_bib27","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1001\/jama.2012.144878","article-title":"Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis","volume":"308","author":"Van der Meer","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2016.09.017_bib28","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1053\/gast.2002.33023","article-title":"Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C","volume":"122","author":"Poynard","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.09.017_bib29","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1002\/hep.22694","article-title":"Clinical, virologic, histologic, and biochemical outcomes after successful HCV therapy: a 5-year follow-up of 150 patients","volume":"49","author":"George","year":"2009","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib30","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/S1665-2681(19)30840-3","article-title":"Long term changes in liver histology following treatment of chronic hepatitis C virus","volume":"13","author":"Shiffman","year":"2014","journal-title":"Ann Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib31","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1002\/hep.20073","article-title":"Effect of peginterferon alfa-2a on liver histology in chronic hepatitis C: a meta-analysis of individual patient data","volume":"39","author":"Camm\u00e0","year":"2004","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib32","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP1570","article-title":"Biomarkers of liverinjury for hepatitis clinical trials: a meta-analysis of longitudinal studies","volume":"15","author":"Poynard","year":"2010","journal-title":"Antivir Ther"},{"key":"10.1016\/j.cmi.2016.09.017_bib33","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1111\/j.1365-2036.2010.04500.x","article-title":"Assessment of liver fibrosis before and after antiviral therapy by different serum marker panels in patients with chronic hepatitis C","volume":"33","author":"Martinez","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.09.017_bib34","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jhep.2013.05.015","article-title":"Slow regression of liver fibrosis presumed by repeated biomarkers after virological cure in patients with chronic hepatitis C","volume":"59","author":"Poynard","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib35","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.antiviral.2009.04.002","article-title":"The longitudinal quantitative assessment by transient elastography of chronic hepatitis C patients treated with pegylated interferon alpha-2b and ribavirin","volume":"83","author":"Ogawa","year":"2009","journal-title":"Antiviral Res"},{"key":"10.1016\/j.cmi.2016.09.017_bib36","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1111\/j.1365-2893.2008.01055.x","article-title":"Changes of non-invasive markers and FibroScan values during HCV treatment","volume":"16","author":"Vergniol","year":"2009","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cmi.2016.09.017_bib37","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1111\/j.1365-2036.2011.04765.x","article-title":"Liver stiffness diminishes with antiviral response in chronic hepatitis C","volume":"34","author":"Hezode","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.09.017_bib38","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.dld.2013.03.023","article-title":"Longitudinal assessment of liver stiffness in patients undergoing antiviral treatment for hepatitis C","volume":"45","author":"Stasi","year":"2013","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cmi.2016.09.017_bib39","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jhep.2013.03.013","article-title":"The diagnostic accuracy of Fibroscan for cirrhosis is influenced by liver morphometry in HCV patients with a sustained virological response","volume":"59","author":"D\u2019Ambrosio","year":"2013","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib40","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.cgh.2016.01.009","article-title":"Serum biomarkers indicates long-term reduction in liver fibrosis, in patients with sustained viral responses to hepatitis C virus treatment","volume":"14","author":"Lu","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib41","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/jvh.12382","article-title":"Successful treatment with telaprevir-based regimens for chronic hepatitis C results in significant improvements to serum markers of liver fibrosis","volume":"22","author":"Haseltine","year":"2015","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.cmi.2016.09.017_bib42","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1097\/MEG.0000000000000533","article-title":"Evaluation of advanced fibrosis measured by transient elastography after hepatitis C virus protease inhibitor-based triple therapy","volume":"28","author":"S\u00e1ez-Royuela","year":"2016","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib43","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/hepr.12621","article-title":"Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients","volume":"46","author":"Miyaki","year":"2016","journal-title":"Hepatol Res"},{"key":"10.1016\/j.cmi.2016.09.017_bib44","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.dld.2015.09.015","article-title":"Early changes in dynamic biomarkers of liver fibrosis in hepatitis C virus-infected patients treated with sofosbuvir","volume":"48","author":"Bernuth","year":"2016","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.cmi.2016.09.017_bib45","first-page":"P108","article-title":"Regression of advanced fibrosis or cirrhosis measured by elastography in patients with chronic hepatitis C who achieve sustained virologic response after treatment for HCV","author":"Crissien","year":"2015","journal-title":"AASLD"},{"key":"10.1016\/j.cmi.2016.09.017_bib46","doi-asserted-by":"crossref","first-page":"e0159413","DOI":"10.1371\/journal.pone.0159413","article-title":"Liver stiffness decreases rapidly in response to successful hepatitis C treatment and then plateaus","volume":"11","author":"Chekuri","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.cmi.2016.09.017_bib47","doi-asserted-by":"crossref","first-page":"561","DOI":"10.12659\/AOT.893640","article-title":"Interferon-free sofosbuvir-based anti-HCV therapy after liver transplantation","volume":"20","author":"Seifert","year":"2015","journal-title":"Ann Transplant"},{"key":"10.1016\/j.cmi.2016.09.017_bib48","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1093\/cid\/civ396","article-title":"Long-term treatment outcomes of patients infected with hepatitis C virus: a systematic review and meta-analysis of the survival benefit of achieving a sustained virological response","volume":"61","author":"Simmons","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2016.09.017_bib49","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s12879-015-0748-8","article-title":"Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits","volume":"15","author":"Smith-Palmer","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.cmi.2016.09.017_bib50","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1111\/apt.13085","article-title":"Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C","volume":"41","author":"Rutter","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.09.017_bib51","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/s10620-014-3361-6","article-title":"Lower incidence of hepatocellular carcinoma and cirrhosis in hepatitis C patients with sustained virological response by pegylated interferon and ribavirin","volume":"60","author":"Moon","year":"2015","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.cmi.2016.09.017_bib52","doi-asserted-by":"crossref","first-page":"329","DOI":"10.7326\/0003-4819-158-5-201303050-00005","article-title":"Eradication of hepatitis C virus infection and the development of hepatocellular carcinoma: a meta-analysis of observational studies","volume":"158","author":"Morgan","year":"2013","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cmi.2016.09.017_bib53","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s40261-015-0338-y","article-title":"Achieving sustained virological response in hepatitis c reduces the long-term risk of hepatocellular carcinoma: an updated meta-analysis employing relative and absolute outcome measures","volume":"35","author":"Messori","year":"2015","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.cmi.2016.09.017_bib54","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/apt.12350","article-title":"Durability of SVR in chronic hepatitis C patients treated with peginterferon-\u03b12a\/ribavirin in combination with a direct-acting anti-viral","volume":"38","author":"Rutter","year":"2013","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.09.017_bib55","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","article-title":"Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study","volume":"148","author":"Curry","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.09.017_bib56","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","article-title":"Ledipasvir and Sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease","volume":"149","author":"Charlton","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cmi.2016.09.017_bib57","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1002\/hep.28446","article-title":"Daclatasvir with sofosbuvir and ribavirin for HCV infection with advanced cirrhosis or post-liver transplant recurrence","volume":"63","author":"Poordad","year":"2016","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib58","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1002\/hep.27937","article-title":"Multicenter experience using simeprevir and sofosbuvir with or without ribavirin to treat hepatitis C genotype 1 in patients with cirrhosis","volume":"62","author":"Agel","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cmi.2016.09.017_bib59","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/apt.13343","article-title":"Improvement of liver function parameters in advanced HCV-associated liver cirrhosis by IFN-free antiviral therapies","volume":"42","author":"Deterding","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.cmi.2016.09.017_bib60","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1016\/j.jhep.2016.01.029","article-title":"Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis","volume":"64","author":"Foster","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib61","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jhep.2016.05.027","article-title":"Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension","volume":"65","author":"Mandorfer","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib62","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected early tumor recurrence in patients with hepatitis C virus -related hepatocellular carcinoma undergoing interferon-free therapy: a note of caution","volume":"65","author":"Reig","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib63","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib64","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.jhep.2016.05.045","article-title":"Lack of evidence of an effect of direct-acting antivirals on the recurrence of hepatocellular carcinoma: data from three ANRS cohorts","volume":"65","author":"ANRS Collaborative Study Group on Hepatocellular Carcinoma","year":"2016","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cmi.2016.09.017_bib65","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1517\/13543784.2015.1057568","article-title":"Current drugs in early development for treating hepatitis C virus-related hepatic fibrosis","volume":"24","author":"Jaroszewicz","year":"2015","journal-title":"Expert Opin Investig Drugs"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16304232?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X16304232?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:21:14Z","timestamp":1761117674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X16304232"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":65,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["S1198743X16304232"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2016.09.017","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of assessing liver fibrosis in management of chronic hepatitis C virus infection","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2016.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}